Cytokeratin 17 was detected in immersion fixed paraffin-embedded sections of mouse thymus using Mouse Anti-Human/Mouse Cytokeratin 17, Monoclonal Antibody (Catalog # MAB11571) at 0.1ug/mL at 37 °Celsius for 4 minutes. Before incubation with the primary antibody, tissue underwent an all-in-one dewaxing and antigen retrieval preprocessing using PreTreatment Module (PT Module) and Dewax and HIER Buffer H (pH 9; Epredia Catalog # TA-999-DHBH). Tissue was stained using the Alexa Fluor™ 647 Goat anti-Mouse IgG Secondary Antibody at 1:200 at 37 ° Celsius for 2 minutes. (Yellow; Lunaphore Catalog # DR647MS) and counterstained with DAPI (blue; Lunaphore Catalog # DR100). Specific staining was localized to the cytoplasm. Protocol available in COMET™ Panel Builder.

Detection of Cytokeratin 17 in Human Prostate.

Cytokeratin 17 was detected in immersion fixed paraffin-embedded sections of human prostate using Mouse Anti-Human Cytokeratin 17 Monoclonal Antibody (Catalog # MAB11571) at 5 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001) or the HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Detection of Cytokeratin 17 in Human Squamous Cell Carcinoma.

Cytokeratin 17 was detected in immersion fixed paraffin-embedded sections of human squamous cell carcinoma using Mouse Anti-Human Cytokeratin 17 Monoclonal Antibody (Catalog # MAB11571) at 5 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001) or the HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Detection of Human Cytokeratin 17 by Western Blot.

Western Blot shows lysates of MDA-MB-468 human breast cancer cell line and A431 human epithelial carcinoma cell line. PVDF membrane was probed with 2 µg/ml of Mouse Anti-Human Cytokeratin 17 Monoclonal Antibody (Catalog # MAB11571) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for Cytokeratin 17 at approximately 53 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.

Detection of Cytokeratin 17 in MDA-MB-468 cells (Positive) and Ramos cells (Negative).

Cytokeratin 17 was detected in fixed MDA-MB-468 human breast cancer cell line (Positive) and absent in Ramos human Burkitt's lymphoma cell line (Negative) using Mouse Anti-Human Cytokeratin 17 Monoclonal Antibody (Catalog # MAB11571) at 8 µg/ml for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to the cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Detection of Human Cytokeratin 17 by Simple Western^TM.

Simple Western shows lysates of MDA-MB-468 human breast cancer cell line, loaded at 0.5 mg/ml. A specific band was detected for Cytokeratin 17 at approximately 53 kDa (as indicated) using 100 µg/mL of Mouse Anti-Human Cytokeratin 17 Monoclonal Antibody (Catalog # MAB11571). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

View 3 more images

Applications for Human Cytokeratin 17 Antibody

Application

Recommended Usage

COMET

0.1 µg/mL
Sample: Immersion fixed paraffin-embedded sections of mouse thymus

Immunocytochemistry

3-25 µg/mL
Sample: fixed MDA-MB-468 human breast cancer cell line (Positive) and absent in Ramos human Burkitt's lymphoma cell line (Negative)

Immunohistochemistry

3-25 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human prostate and of human squamous cell carcinoma

Simple Western

100 µg/mL
Sample: MDA-MB-468 human breast cancer cell line

Western Blot

2 µg/mL
Sample: MDA-MB-468 human breast cancer cell line and A431 human epithelial carcinoma cell line

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute lyophilized material at 0.2mg/ml in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Cytokeratin 17

Cytokeratin 17 (KRT17) is a 48 kDa, 432 aa type I keratin that has been studied in several types of cancer. KRT17 promotes epithelial cell proliferation and tumor growth in skin. Many studies have shown KRT17 overexpression in many cancers including cervical, oral, ovarian, gastric, lung and pancreatic cancer among others. In certain types of breast cancer, KRT17 overexpression has been associated with poor prognosis. KRT17 expression is closely associated with prognosis in cancer and can be a novel therapeutic target.

References

Tang S, Liu W, Yong L, Liu D, Lin X, Huang Y, Wang H, Cai F. Reduced Expression of KRT17 Predicts Poor Prognosis in HER2high Breast Cancer. Biomolecules. 2022 Aug 25;12(9):1183. doi: 10.3390/biom12091183. PMID: 36139022; PMCID: PMC9496156.
Hu H, Xu DH, Huang XX, Zhu CC, Xu J, Zhang ZZ, Zhao G. Keratin17 Promotes Tumor Growth and is Associated with Poor Prognosis in Gastric Cancer. J Cancer. 2018 Jan 1;9(2):346-357. doi: 10.7150/jca.19838. PMID: 29344281; PMCID: PMC5771342.
Li D, Ni XF, Tang H, Zhang J, Zheng C, Lin J, Wang C, Sun L, Chen B. KRT17 Functions as a Tumor Promoter and Regulates Proliferation, Migration and Invasion in Pancreatic Cancer via mTOR/S6k1 Pathway. Cancer Manag Res. 2020 Mar 19;12:2087-2095. doi: 10.2147/CMAR.S243129. PMID: 32256116; PMCID: PMC7090205.

Long Name

Cytokeratin 17/KRT17

Alternate Names

CK-17, cytokeratin-17, K17, keratin 17, type I, keratin, type I cytoskeletal 17, PCHC1

Entrez Gene IDs

3872 (Human); 16667 (Mouse); 287702 (Rat)

Gene Symbol

Q04695

UniProt

Q04695 (Human)

Additional Cytokeratin 17 Products

Product Documents for Human Cytokeratin 17 Antibody

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS

Product Specific Notices for Human Cytokeratin 17 Antibody

For research use only

Citations
Reviews

Human Cytokeratin 17 Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB11571

Key Product Details

Species Reactivity

Applications

Label

Antibody Source

View all Cytokeratin 17 Antibodies »

Product Specifications

Immunogen

Specificity

Clonality

Host

Isotype

Scientific Data Images for Human Cytokeratin 17 Antibody

Cytokeratin 17 in Mouse Thymus via seqIF™ staining on COMET™​